Intrinsic value of Allscripts Healthcare Solutions - MDRX

Previous Close

$14.67

  Intrinsic Value

$13.75

stock screener

  Rating & Target

hold

-6%

Previous close

$14.67

 
Intrinsic value

$13.75

 
Up/down potential

-6%

 
Rating

hold

We calculate the intrinsic value of MDRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 2.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  16.60
  15.44
  14.40
  13.46
  12.61
  11.85
  11.16
  10.55
  9.99
  9.49
  9.04
  8.64
  8.28
  7.95
  7.65
  7.39
  7.15
  6.93
  6.74
  6.57
  6.41
  6.27
  6.14
  6.03
  5.93
  5.83
  5.75
  5.67
  5.61
  5.55
Revenue, $m
  2,106
  2,431
  2,781
  3,155
  3,553
  3,974
  4,418
  4,884
  5,372
  5,882
  6,414
  6,968
  7,545
  8,144
  8,768
  9,415
  10,088
  10,788
  11,515
  12,271
  13,058
  13,877
  14,729
  15,617
  16,542
  17,507
  18,514
  19,564
  20,661
  21,807
Variable operating expenses, $m
  1,975
  2,233
  2,510
  2,807
  3,123
  3,456
  3,808
  4,178
  4,565
  4,969
  5,085
  5,525
  5,982
  6,458
  6,952
  7,465
  7,999
  8,554
  9,130
  9,730
  10,354
  11,003
  11,679
  12,383
  13,116
  13,881
  14,680
  15,513
  16,382
  17,291
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  1,975
  2,233
  2,510
  2,807
  3,123
  3,456
  3,808
  4,178
  4,565
  4,969
  5,085
  5,525
  5,982
  6,458
  6,952
  7,465
  7,999
  8,554
  9,130
  9,730
  10,354
  11,003
  11,679
  12,383
  13,116
  13,881
  14,680
  15,513
  16,382
  17,291
Operating income, $m
  131
  198
  271
  348
  430
  518
  610
  706
  807
  913
  1,328
  1,443
  1,562
  1,687
  1,816
  1,950
  2,089
  2,234
  2,385
  2,541
  2,704
  2,874
  3,050
  3,234
  3,426
  3,626
  3,834
  4,052
  4,279
  4,516
EBITDA, $m
  797
  921
  1,053
  1,195
  1,346
  1,505
  1,673
  1,849
  2,034
  2,227
  2,429
  2,639
  2,857
  3,084
  3,320
  3,566
  3,821
  4,085
  4,361
  4,647
  4,945
  5,255
  5,578
  5,914
  6,265
  6,630
  7,011
  7,409
  7,825
  8,258
Interest expense (income), $m
  42
  95
  126
  159
  195
  234
  275
  319
  364
  412
  463
  516
  570
  628
  687
  749
  814
  880
  950
  1,022
  1,097
  1,175
  1,257
  1,341
  1,429
  1,521
  1,617
  1,716
  1,820
  1,929
  2,042
Earnings before tax, $m
  36
  72
  111
  153
  196
  243
  291
  342
  395
  450
  813
  873
  935
  999
  1,067
  1,136
  1,209
  1,284
  1,363
  1,444
  1,529
  1,617
  1,709
  1,805
  1,905
  2,009
  2,118
  2,232
  2,350
  2,474
Tax expense, $m
  10
  20
  30
  41
  53
  65
  79
  92
  107
  121
  219
  236
  252
  270
  288
  307
  326
  347
  368
  390
  413
  437
  461
  487
  514
  542
  572
  603
  635
  668
Net income, $m
  26
  53
  81
  111
  143
  177
  212
  249
  288
  328
  593
  637
  682
  730
  779
  830
  882
  937
  995
  1,054
  1,116
  1,181
  1,248
  1,318
  1,391
  1,467
  1,546
  1,629
  1,716
  1,806

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  4,932
  5,693
  6,513
  7,389
  8,321
  9,307
  10,346
  11,437
  12,580
  13,774
  15,020
  16,318
  17,669
  19,073
  20,533
  22,050
  23,626
  25,265
  26,968
  28,739
  30,581
  32,498
  34,494
  36,574
  38,741
  41,001
  43,358
  45,818
  48,387
  51,071
Adjusted assets (=assets-cash), $m
  4,932
  5,693
  6,513
  7,389
  8,321
  9,307
  10,346
  11,437
  12,580
  13,774
  15,020
  16,318
  17,669
  19,073
  20,533
  22,050
  23,626
  25,265
  26,968
  28,739
  30,581
  32,498
  34,494
  36,574
  38,741
  41,001
  43,358
  45,818
  48,387
  51,071
Revenue / Adjusted assets
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
  0.427
Average production assets, $m
  3,614
  4,171
  4,772
  5,414
  6,097
  6,819
  7,581
  8,380
  9,218
  10,093
  11,006
  11,957
  12,946
  13,975
  15,045
  16,157
  17,312
  18,512
  19,760
  21,058
  22,408
  23,813
  25,275
  26,799
  28,387
  30,042
  31,770
  33,572
  35,455
  37,421
Working capital, $m
  -114
  -131
  -150
  -170
  -192
  -215
  -239
  -264
  -290
  -318
  -346
  -376
  -407
  -440
  -473
  -508
  -545
  -583
  -622
  -663
  -705
  -749
  -795
  -843
  -893
  -945
  -1,000
  -1,056
  -1,116
  -1,178
Total debt, $m
  2,093
  2,653
  3,255
  3,899
  4,584
  5,309
  6,072
  6,874
  7,715
  8,592
  9,508
  10,462
  11,455
  12,487
  13,560
  14,675
  15,834
  17,038
  18,290
  19,591
  20,945
  22,354
  23,822
  25,350
  26,943
  28,604
  30,336
  32,145
  34,033
  36,005
Total liabilities, $m
  3,625
  4,184
  4,787
  5,431
  6,116
  6,840
  7,604
  8,406
  9,246
  10,124
  11,040
  11,994
  12,986
  14,019
  15,092
  16,207
  17,365
  18,570
  19,821
  21,123
  22,477
  23,886
  25,353
  26,882
  28,475
  30,135
  31,868
  33,676
  35,565
  37,537
Total equity, $m
  1,307
  1,509
  1,726
  1,958
  2,205
  2,466
  2,742
  3,031
  3,334
  3,650
  3,980
  4,324
  4,682
  5,054
  5,441
  5,843
  6,261
  6,695
  7,146
  7,616
  8,104
  8,612
  9,141
  9,692
  10,266
  10,865
  11,490
  12,142
  12,823
  13,534
Total liabilities and equity, $m
  4,932
  5,693
  6,513
  7,389
  8,321
  9,306
  10,346
  11,437
  12,580
  13,774
  15,020
  16,318
  17,668
  19,073
  20,533
  22,050
  23,626
  25,265
  26,967
  28,739
  30,581
  32,498
  34,494
  36,574
  38,741
  41,000
  43,358
  45,818
  48,388
  51,071
Debt-to-equity ratio
  1.600
  1.760
  1.890
  1.990
  2.080
  2.150
  2.210
  2.270
  2.310
  2.350
  2.390
  2.420
  2.450
  2.470
  2.490
  2.510
  2.530
  2.540
  2.560
  2.570
  2.580
  2.600
  2.610
  2.620
  2.620
  2.630
  2.640
  2.650
  2.650
  2.660
Adjusted equity ratio
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265
  0.265

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  26
  53
  81
  111
  143
  177
  212
  249
  288
  328
  593
  637
  682
  730
  779
  830
  882
  937
  995
  1,054
  1,116
  1,181
  1,248
  1,318
  1,391
  1,467
  1,546
  1,629
  1,716
  1,806
Depreciation, amort., depletion, $m
  667
  723
  783
  847
  915
  987
  1,063
  1,143
  1,227
  1,315
  1,101
  1,196
  1,295
  1,398
  1,505
  1,616
  1,731
  1,851
  1,976
  2,106
  2,241
  2,381
  2,528
  2,680
  2,839
  3,004
  3,177
  3,357
  3,545
  3,742
Funds from operations, $m
  693
  775
  864
  958
  1,059
  1,164
  1,276
  1,393
  1,515
  1,643
  1,694
  1,833
  1,977
  2,127
  2,283
  2,445
  2,614
  2,789
  2,971
  3,160
  3,357
  3,562
  3,775
  3,998
  4,229
  4,471
  4,723
  4,986
  5,261
  5,548
Change in working capital, $m
  -16
  -18
  -19
  -20
  -21
  -23
  -24
  -25
  -26
  -28
  -29
  -30
  -31
  -32
  -34
  -35
  -36
  -38
  -39
  -41
  -42
  -44
  -46
  -48
  -50
  -52
  -54
  -57
  -59
  -62
Cash from operations, $m
  709
  793
  883
  979
  1,080
  1,187
  1,300
  1,418
  1,542
  1,671
  1,723
  1,863
  2,008
  2,159
  2,317
  2,480
  2,650
  2,826
  3,010
  3,201
  3,399
  3,606
  3,821
  4,045
  4,279
  4,523
  4,778
  5,043
  5,320
  5,610
Maintenance CAPEX, $m
  -310
  -361
  -417
  -477
  -541
  -610
  -682
  -758
  -838
  -922
  -1,009
  -1,101
  -1,196
  -1,295
  -1,398
  -1,505
  -1,616
  -1,731
  -1,851
  -1,976
  -2,106
  -2,241
  -2,381
  -2,528
  -2,680
  -2,839
  -3,004
  -3,177
  -3,357
  -3,545
New CAPEX, $m
  -515
  -558
  -601
  -642
  -683
  -722
  -761
  -800
  -837
  -875
  -913
  -951
  -990
  -1,029
  -1,070
  -1,112
  -1,155
  -1,200
  -1,248
  -1,298
  -1,350
  -1,405
  -1,463
  -1,524
  -1,588
  -1,656
  -1,727
  -1,803
  -1,882
  -1,966
Cash from investing activities, $m
  -825
  -919
  -1,018
  -1,119
  -1,224
  -1,332
  -1,443
  -1,558
  -1,675
  -1,797
  -1,922
  -2,052
  -2,186
  -2,324
  -2,468
  -2,617
  -2,771
  -2,931
  -3,099
  -3,274
  -3,456
  -3,646
  -3,844
  -4,052
  -4,268
  -4,495
  -4,731
  -4,980
  -5,239
  -5,511
Free cash flow, $m
  -115
  -126
  -135
  -141
  -144
  -145
  -143
  -140
  -134
  -126
  -200
  -189
  -177
  -164
  -150
  -136
  -121
  -105
  -89
  -73
  -56
  -40
  -23
  -6
  11
  29
  46
  63
  81
  98
Issuance/(repayment) of debt, $m
  516
  560
  602
  644
  685
  725
  764
  802
  840
  878
  916
  954
  993
  1,032
  1,073
  1,115
  1,159
  1,204
  1,252
  1,302
  1,354
  1,409
  1,467
  1,528
  1,593
  1,661
  1,733
  1,808
  1,888
  1,973
Issuance/(repurchase) of shares, $m
  160
  149
  136
  121
  103
  84
  63
  40
  15
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  676
  709
  738
  765
  788
  809
  827
  842
  855
  878
  916
  954
  993
  1,032
  1,073
  1,115
  1,159
  1,204
  1,252
  1,302
  1,354
  1,409
  1,467
  1,528
  1,593
  1,661
  1,733
  1,808
  1,888
  1,973
Total cash flow (excl. dividends), $m
  560
  582
  603
  624
  644
  664
  683
  702
  721
  752
  716
  765
  816
  868
  923
  979
  1,038
  1,099
  1,163
  1,229
  1,298
  1,370
  1,445
  1,523
  1,604
  1,690
  1,779
  1,872
  1,969
  2,071
Retained Cash Flow (-), $m
  -186
  -202
  -217
  -232
  -247
  -261
  -275
  -289
  -303
  -317
  -330
  -344
  -358
  -372
  -387
  -402
  -418
  -434
  -451
  -469
  -488
  -508
  -529
  -551
  -574
  -599
  -625
  -652
  -681
  -711
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  38
  44
  51
  58
  66
  75
  83
  93
  103
  113
  124
  135
  146
  158
  171
  184
  198
  212
  227
  242
  258
  274
  291
  309
  328
  347
  368
  389
  411
  434
Cash available for distribution, $m
  374
  380
  386
  392
  397
  403
  408
  413
  418
  435
  386
  421
  458
  496
  536
  577
  620
  665
  711
  759
  810
  862
  916
  972
  1,030
  1,091
  1,154
  1,220
  1,288
  1,360
Discount rate, %
  8.10
  8.51
  8.93
  9.38
  9.85
  10.34
  10.85
  11.40
  11.97
  12.57
  13.19
  13.85
  14.55
  15.27
  16.04
  16.84
  17.68
  18.57
  19.49
  20.47
  21.49
  22.57
  23.69
  24.88
  26.12
  27.43
  28.80
  30.24
  31.75
  33.34
PV of cash for distribution, $m
  346
  323
  299
  274
  248
  223
  198
  174
  151
  133
  99
  89
  78
  68
  58
  48
  39
  31
  24
  18
  14
  10
  7
  5
  3
  2
  1
  1
  0
  0
Current shareholders' claim on cash, %
  94.3
  90.0
  86.7
  84.2
  82.4
  81.1
  80.2
  79.7
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6
  79.6

Allscripts Healthcare Solutions, Inc. (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions. The Population Health segment includes the sale of health management and coordinated care solutions, which focus on hospitals, health systems, other care facilities and accountable care organizations (ACOs). The Netsmart segment provides software and technology solutions to the health and human services industry, which includes behavioral health, addiction treatment, intellectual and developmental disability services, child and family services and public health segments, as well as to post-acute home care organizations.

FINANCIAL RATIOS  of  Allscripts Healthcare Solutions (MDRX)

Valuation Ratios
P/E Ratio 882.7
Price to Sales 1.7
Price to Book 2.1
Price to Tangible Book
Price to Cash Flow 9.8
Price to Free Cash Flow 20.2
Growth Rates
Sales Growth Rate 11.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 102.9%
Cap. Spend. - 3 Yr. Gr. Rate 3.5%
Financial Strength
Quick Ratio 4
Current Ratio 0
LT Debt to Equity 105.8%
Total Debt to Equity 108%
Interest Coverage 1
Management Effectiveness
Return On Assets -0.2%
Ret/ On Assets - 3 Yr. Avg. -1.2%
Return On Total Capital 0.1%
Ret/ On T. Cap. - 3 Yr. Avg. -1.2%
Return On Equity 0.2%
Return On Equity - 3 Yr. Avg. -1.7%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 43.3%
Gross Margin - 3 Yr. Avg. 41.6%
EBITDA Margin 12.8%
EBITDA Margin - 3 Yr. Avg. 11.5%
Operating Margin 3.9%
Oper. Margin - 3 Yr. Avg. 1.1%
Pre-Tax Margin -1%
Pre-Tax Margin - 3 Yr. Avg. -1.9%
Net Profit Margin 0.2%
Net Profit Margin - 3 Yr. Avg. -1.6%
Effective Tax Rate 120%
Eff/ Tax Rate - 3 Yr. Avg. 141%
Payout Ratio 0%

MDRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MDRX stock intrinsic value calculation we used $1806 million for the last fiscal year's total revenue generated by Allscripts Healthcare Solutions. The default revenue input number comes from 2017 income statement of Allscripts Healthcare Solutions. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MDRX stock valuation model: a) initial revenue growth rate of 16.6% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 8.1%, whose default value for MDRX is calculated based on our internal credit rating of Allscripts Healthcare Solutions, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Allscripts Healthcare Solutions.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MDRX stock the variable cost ratio is equal to 96.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MDRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 6% for Allscripts Healthcare Solutions.

Corporate tax rate of 27% is the nominal tax rate for Allscripts Healthcare Solutions. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MDRX stock is equal to 2.1%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MDRX are equal to 171.6%.

Life of production assets of 10 years is the average useful life of capital assets used in Allscripts Healthcare Solutions operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MDRX is equal to -5.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1121 million for Allscripts Healthcare Solutions - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 181 million for Allscripts Healthcare Solutions is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Allscripts Healthcare Solutions at the current share price and the inputted number of shares is $2.7 billion.

RELATED COMPANIES Price Int.Val. Rating
CERN Cerner 64.86 28.89  sell
QSII Quality System 21.91 2.94  str.sell
CPSI Computer Progr 27.30 13.75  str.sell
UNH UnitedHealth G 263.10 401.67  str.buy
MTBC Medical Transc 4.39 39.14  str.buy
NH NantHealth 2.34 0.02  str.sell
MMM 3M 203.15 175.63  hold
MCK McKesson 127.09 355.02  str.buy
ATHN athenahealth 150.48 75.39  sell

COMPANY NEWS

▶ Allscripts will sell 51 percent stake in Netsmart   [Aug-07-18 03:34PM  American City Business Journals]
▶ AllScripts: 2Q Earnings Snapshot   [04:13PM  Associated Press]
▶ Allscripts closes acquisition of HealthGrid   [May-21-18 08:01AM  GlobeNewswire]
▶ AllScripts: 1Q Earnings Snapshot   [May-03-18 04:50PM  Associated Press]
▶ MedStar study: Electronic health records might be leading to patient harm   [Mar-29-18 03:01PM  American City Business Journals]
▶ Allscripts launches industrys first machine learning EHR   [Mar-06-18 08:01AM  GlobeNewswire]
▶ Allscripts, Lyft partner on health care transportation   [Mar-05-18 08:43AM  MarketWatch]
▶ [$$] Patients Missing Doctor Visits Get Helping Hand   [07:30AM  The Wall Street Journal]
▶ AllScripts meets 4Q profit forecasts   [04:27PM  Associated Press]
▶ Allscripts Names Dennis Olis Chief Financial Officer   [Jan-31-18 04:01PM  GlobeNewswire]
▶ Allscripts to acquire Practice Fusion business   [Jan-08-18 08:01AM  GlobeNewswire]
▶ Allscripts to attend upcoming investor events   [Dec-04-17 04:01PM  GlobeNewswire]
▶ Gippsland Health Alliance selects Allscripts EMR   [Nov-06-17 04:01PM  GlobeNewswire]
▶ AllScripts reports 3Q loss   [Nov-02-17 05:26PM  Associated Press]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.